Sanofi (SNY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
https://seekingalpha.com/article/4793881-sanofi-sny-presents-at-goldman-sachs-46th-annual-global-healthcare-conference-transcript?source=feed_sector_transcripts
Jun 10, 2025 -
0
Sanofi (SNY) ECTRIMS 2024 Investor Science Call Transcript
https://seekingalpha.com/article/4722380-sanofi-sny-ectrims-2024-investor-science-call-transcript?source=feed_sector_transcripts
Sep 20, 2024 - Sanofi (NASDAQ:SNY) ECTRIMS 2024 Investor Science Call September 20, 2024 10:00 AM ETCompany ParticipantsThomas Kudsk - IRJiwon Oh - MD, PhD, St.
0
Eli Lilly's Weekly Insulin Shot Meets Two Late-Stage Study Goals
https://www.zacks.com/stock/news/2333037/eli-lilly-s-weekly-insulin-shot-meets-two-late-stage-study-goals?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2333037
Sep 06, 2024 - Data from two late-stage studies show that LLY's once-weekly insulin injections achieved results that are similar to daily insulin shots.
0
Pharma Stock Roundup: EU Nod for Expanded Use of MRK's Keytruda & More
https://www.zacks.com/stock/news/2332784/pharma-stock-roundup-eu-nod-for-expanded-use-of-mrk-s-keytruda-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2332784
Sep 06, 2024 - European Commission approves expanded use of Merck's Keytruda in bladder cancer. Sanofi & Lilly announce data from phase III studies on pipeline candidates.
0
Novavax Stock Up 9% on FDA Nod for Updated COVID-19 Vaccine
https://www.zacks.com/stock/news/2330525/novavax-stock-up-9-on-fda-nod-for-updated-covid-19-vaccine?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2330525
Sep 02, 2024 - The FDA authorization for NVAX's updated COVID-19 vaccine makes it the only non-mRNA vaccine option in the country.
0
SNY's MS Drug Meets Goal in One Phase III Study; Misses in Two Others
https://www.zacks.com/stock/news/2330244/sny-s-ms-drug-meets-goal-in-one-phase-iii-study-misses-in-two-others?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2330244
Sep 02, 2024 - Sanofi's HERCULES phase III study on tolebrutinib meets primary endpoint, showing an improvement in delaying time to onset of confirmed disability progression.
0
Regeneron's Bispecific Antibody Obtains EC Nod for Lymphoma
https://www.zacks.com/stock/news/2327848/regeneron-s-bispecific-antibody-obtains-ec-nod-for-lymphoma?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2327848
Aug 27, 2024 - REGN's oncology portfolio gets a boost with the approval of odronextamab for treating follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).
0
How Should You Play AstraZeneca (AZN) After Q2 Beat, View Raise?
https://www.zacks.com/stock/news/2316191/how-should-you-play-astrazeneca-azn-after-q2-beat-view-raise?cid=CS-ZC-FT-analyst_blog|rank_focused-2316191
Aug 16, 2024 - AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge, with several candidates having blockbuster potential.
0
The Zacks Analyst Blog Highlights Meta Platforms, Sanofi, CME and The Cato
https://www.zacks.com/stock/news/2322681/the-zacks-analyst-blog-highlights-meta-platforms-sanofi-cme-and-the-cato?cid=CS-ZC-FT-press_releases-2322681
Aug 15, 2024 - Meta Platforms, Sanofi, CME and The Cato are part of the Zacks top Analyst Blog.
0
Top Stock Reports for Meta, Sanofi & CME
https://www.zacks.com/commentary/2322068/top-stock-reports-for-meta-sanofi-cme?cid=CS-ZC-FT-research_daily-2322068
Aug 14, 2024 - Today's Research Daily features new research reports on 12 major stocks, including Meta Platforms, Inc. (META), Sanofi (SNY) and CME Group Inc. (CME), as well a micro-cap stock The Cato Corporation (CATO).
0
Page 1>